| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3284850 | Clinical Gastroenterology and Hepatology | 2008 | 6 Pages |
Abstract
Infliximab seemed effective in IBD and generally was well tolerated. However, rare but severe adverse events occurred, and patients receiving infliximab therefore should be selected carefully and monitored closely. No lymphomas and no increased risk of cancer were observed.
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Sarah Caspersen, Margarita Elkjaer, Lene Riis, Natalia Pedersen, Christian Mortensen, Tine Jess, Pernille Sarto, Tanja S. Hansen, Vibeke Wewer, Flemming Bendtsen, Flemming Moesgaard, Pia Munkholm,